With multiple myeloma or bone metastases comes the risk of skeletal-related events (SREs).
Without early detection, the consequences of those SREs can be devastating.
90% of men with advanced prostate cancer1
75% of patients with advanced breast cancer2
40% of patients with advanced lung cancer2
100% of patients with multiple myeloma2
In one study,* SREs were seen at
diagnosis of bone mets in:3
Within 24 months, the incidence
of SREs increased by more than:3
SREs may manifest in
various forms, such as:4–5
They can cause a range of potentially
devastating complications, including:4–8
Spinal cord compression
Radiation to the bone
Surgery to the bone
With cancer patients increasingly living longer,11
their quality of life is becoming increasingly important.
Assess your patient’s bone health before SREs occur,
using the below recommendations as a guide.
In prostate cancer patients, screen for bone mets using bone scans at a recommended frequency of:1
Every 3 to 6 months in patients with a rapid PSADT (<10 months).
Every 6 to 12 months in patients with a slower PSADT (>10 months).
– CUA-CUOG CRPC Guidelines
In breast cancer patients, screen for bone mets in:12
All patients with recurrent/Stage IV disease, using a bone scan or sodium fluoride PET/CT, as well as radiographs of any long or weight-bearing bones that are painful or appear abnormal on bone scan.
All other patients presenting with localized bone pain or elevated alkaline phosphatase, using a bone scan.
– NCCN Breast Cancer Guidelines
In patients with suspected multiple myeloma, screen for osteolytic bone lesions using:13
Whole-body imaging with low-dose CT or FDG PET/CT, as part of the diagnostic work-up.
Skeletal survey in certain circumstances.
Whole-body MRI without contrast, if initial CT or FDG PET/CT is negative.
– NCCN Multiple Myeloma Guidelines
Cancer took so much.
Don’t let SREs take what’s left.